Increlex(R) Phase IIIb Study Results Demonstrating Dose-Dependent Height Velocity Increase In Primary IGFD Short Stature Population And Other Increlex
Tercica, Inc., a wholly-owned subsidiary of Ipsen (Euronext: IPN) today announced Phase IIIb clinical trial results demonstrating that Increlex® (mecasermin (rDNA origin) injection) achieved statistically significant dose-dependent first-year height velocity increases in children with Primary IGF-1 Deficiency (Primary IGFD) when administered as a twice-daily injection. More: continued here
Increlex(R) Phase IIIb Study Results Demonstrating Dose-Dependent Height Velocity Increase In Primary IGFD Short Stature Population And Other Increlex...

Detailed Functional Studies On Androgen Receptor Mild Mutations Demonstrate Their Association With Male Infertility
Mutations in the androgen receptor (AR) gene can cause the androgen insensitivity syndrome (AIS). For complete and severe partial AIS well-characterized in vitro functional assays can be used for genotype-phenotype correlation, however for mild forms of AIS, as associated with male infertility, experimental evidence is scarce or
Detailed Functional Studies On Androgen Receptor Mild Mutations Demonstrate Their Association With Male Infertility...

30 Years Of IVF, UK
Following the success of National Infertility Day on 19th July which this year was in recognition of 30 years of IVF, the national patient organisation would like to congratulate all those who have been successful over the last 30 years with fertility treatment but would also
30 Years Of IVF, UK...